Advances in Management of Atopic Dermatitis: New Therapies and Novel Uses of Existing Treatments

Elizabeth P. Chase, April W. Armstrong

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by intensely pruritic, eczematous changes. First-line therapy includes topical corticosteroids during an exacerbation and long-term emollient use, followed by topical calcineurin inhibitors, phototherapy, and systemic therapy in more difficult cases. The need for more effective AD therapies with safer side effect profiles has pushed researchers to devise new therapies and to recycle traditional treatments for use in a novel manner. Innovative therapies include barrier therapy, novel antistaphylococcal treatments, new immunomodulatory agents, unconventional antipruritic agents, exclusionary diets, and probiotics. Advancements in these options have paved the way for a targeted approach to AD therapy. We will review the latest clinical research exploring these cutting-edge AD treatment modalities and discuss forward-thinking therapy strategies that use conventional AD medications in a novel manner.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalSeminars in Cutaneous Medicine and Surgery
Volume31
Issue number1
DOIs
StatePublished - Mar 2012

Fingerprint

Atopic Dermatitis
Therapeutics
Antipruritics
Emollients
Investigational Therapies
Phototherapy
Probiotics
Adrenal Cortex Hormones
Research Personnel
Diet
Skin

Keywords

  • Atopic dermatitis
  • Barrier cream
  • Biologics
  • Drug
  • Eczema
  • Medication
  • Proactive therapy
  • Systemic
  • Therapy
  • Topical
  • Treatment

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Advances in Management of Atopic Dermatitis : New Therapies and Novel Uses of Existing Treatments. / Chase, Elizabeth P.; Armstrong, April W.

In: Seminars in Cutaneous Medicine and Surgery, Vol. 31, No. 1, 03.2012, p. 17-24.

Research output: Contribution to journalArticle

@article{25a983b6f1d44e298af63bce7ada80aa,
title = "Advances in Management of Atopic Dermatitis: New Therapies and Novel Uses of Existing Treatments",
abstract = "Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by intensely pruritic, eczematous changes. First-line therapy includes topical corticosteroids during an exacerbation and long-term emollient use, followed by topical calcineurin inhibitors, phototherapy, and systemic therapy in more difficult cases. The need for more effective AD therapies with safer side effect profiles has pushed researchers to devise new therapies and to recycle traditional treatments for use in a novel manner. Innovative therapies include barrier therapy, novel antistaphylococcal treatments, new immunomodulatory agents, unconventional antipruritic agents, exclusionary diets, and probiotics. Advancements in these options have paved the way for a targeted approach to AD therapy. We will review the latest clinical research exploring these cutting-edge AD treatment modalities and discuss forward-thinking therapy strategies that use conventional AD medications in a novel manner.",
keywords = "Atopic dermatitis, Barrier cream, Biologics, Drug, Eczema, Medication, Proactive therapy, Systemic, Therapy, Topical, Treatment",
author = "Chase, {Elizabeth P.} and Armstrong, {April W.}",
year = "2012",
month = "3",
doi = "10.1016/j.sder.2011.11.005",
language = "English (US)",
volume = "31",
pages = "17--24",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Advances in Management of Atopic Dermatitis

T2 - New Therapies and Novel Uses of Existing Treatments

AU - Chase, Elizabeth P.

AU - Armstrong, April W.

PY - 2012/3

Y1 - 2012/3

N2 - Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by intensely pruritic, eczematous changes. First-line therapy includes topical corticosteroids during an exacerbation and long-term emollient use, followed by topical calcineurin inhibitors, phototherapy, and systemic therapy in more difficult cases. The need for more effective AD therapies with safer side effect profiles has pushed researchers to devise new therapies and to recycle traditional treatments for use in a novel manner. Innovative therapies include barrier therapy, novel antistaphylococcal treatments, new immunomodulatory agents, unconventional antipruritic agents, exclusionary diets, and probiotics. Advancements in these options have paved the way for a targeted approach to AD therapy. We will review the latest clinical research exploring these cutting-edge AD treatment modalities and discuss forward-thinking therapy strategies that use conventional AD medications in a novel manner.

AB - Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by intensely pruritic, eczematous changes. First-line therapy includes topical corticosteroids during an exacerbation and long-term emollient use, followed by topical calcineurin inhibitors, phototherapy, and systemic therapy in more difficult cases. The need for more effective AD therapies with safer side effect profiles has pushed researchers to devise new therapies and to recycle traditional treatments for use in a novel manner. Innovative therapies include barrier therapy, novel antistaphylococcal treatments, new immunomodulatory agents, unconventional antipruritic agents, exclusionary diets, and probiotics. Advancements in these options have paved the way for a targeted approach to AD therapy. We will review the latest clinical research exploring these cutting-edge AD treatment modalities and discuss forward-thinking therapy strategies that use conventional AD medications in a novel manner.

KW - Atopic dermatitis

KW - Barrier cream

KW - Biologics

KW - Drug

KW - Eczema

KW - Medication

KW - Proactive therapy

KW - Systemic

KW - Therapy

KW - Topical

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84857222418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857222418&partnerID=8YFLogxK

U2 - 10.1016/j.sder.2011.11.005

DO - 10.1016/j.sder.2011.11.005

M3 - Article

C2 - 22361285

AN - SCOPUS:84857222418

VL - 31

SP - 17

EP - 24

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

IS - 1

ER -